Portage Biotech Highlights Its Invariant Natural Killer T-Cell Agonists, PORT-2, PORT-3 Were Well Tolerated
Portage Biotech Highlights Its Invariant Natural Killer T-Cell Agonists, PORT-2, PORT-3 Were Well Tolerated
Preliminary safety data suggests lead iNKT agonists, PORT-2 and PORT-3, are well tolerated supporting continued development
Company continues to work toward multiple clinical readouts in 2022
Portage is accelerating studies by expanding regions and clinical sites; continued advancement of pipeline beyond iNKTs
WESTPORT, Conn., March 31, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG) ("Portage" or the "Company"), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today provided an update on its clinical development programs and announced its development goals for the remainder of 2022.
"We are pleased to report...
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧